Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for Hard-to-Treat ovarian cancer

NCT ID NCT07652073

Disease control Sponsor: Danatlas Pharmaceuticals Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new oral drug called DAT-2645 in up to 30 people with advanced or metastatic ovarian cancer that has a BRCA1/2 mutation or is HRD-positive. Participants take the drug daily in 21-day cycles. The main goal is to see if the drug shrinks tumors, and researchers will also monitor safety and how long any benefit lasts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DAT-2645 tablet
What this could lead to
If successful, this could provide a new oral treatment option for advanced ovarian cancer patients with specific genetic mutations who have run out of standard therapies.
What could go wrong
This is an early Phase 2 trial with only 30 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * sign a written informed consent form * At least 18 years of age (inclusive) * Epithelial ovarian cancer confirmed by histopathology or cytopathology * BRCA1/2 mutation or HRD-positive status * Patients who have failed standard treatment or are unable to tolerate standard treatment * Patients must have received no more than five prior treatment lines * At least one measurable lesion * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 * Bone marrow reserve and organ function must meet the requirements * Negative result on a blood pregnancy test for a woman of childbearing age Exclusion Criteria: * Received small-molecule chemotherapy or targeted therapy within 2 weeks or 5 half-lives prior to the first dose * Received treatment with an anticancer biological therapy within 4 weeks prior to the first dose * Underwent major surgery within 4 weeks prior to the first dose * Has previously received treatment with a PARG inhibitor * Inadequate response to previous PARP inhibitor maintenance therapy * With central nervous system metastases * Patients with clinically significant cardiovascular or cerebrovascular diseases * Uncontrolled active infections requiring intravenous antibiotics or hospitalization * Adverse reactions from prior anticancer therapy have not yet resolved to a grade ≤1

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced or metastatic ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced or metastatic ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    2 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Research site

    Guangzhou, Guangdong, 510050, China

  • Research site

    Beijing, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.